Small molecule tyrosine kinase inhibitors modulated blood immune cell counts in patients with oncogene-driven NSCLC

BACKGROUND: Lack of biomarkers and in vitro models has contributed to inadequate understanding of the mechanisms underlying the inferior clinical response to immune checkpoint inhibitors (ICIs) in patients with oncogene-driven non-small cell lung cancer (NSCLC). METHODS: The effect of small molecule...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Weijie, Zeng, Jie, Chen, Shuai, Lyu, Yue, Toomey, Kyra A., Phan, Chinh T., Yoneda, Ken Y., Li, Tianhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8419812/
https://www.ncbi.nlm.nih.gov/pubmed/34488906
http://dx.doi.org/10.1186/s40364-021-00324-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8419812/
https://www.ncbi.nlm.nih.gov/pubmed/34488906
http://dx.doi.org/10.1186/s40364-021-00324-6

Ejemplares similares